Elevated ORAOV1 expression correlates strongly with aggressive clinicopathological features and promotes an immunosuppressive tumor microenvironment characterized by increased infiltration of pro-tumor immune cells and elevated expression of immune checkpoints such as CTLA4, PD1, and PD-L1. This evidence concerns the gene PDCD1 and neoplasm.